Drugs / MPL-015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07023744 | Jul 2026 → Mar 2028 expected | epilepsy | University of Manitoba | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPL-015 | “CBD Isolate: MPL-015 is a CBD isolate, produced by MediPharm Labs, each mL contains 100mg CBD and 0mg THC.” NCT07023744 ↗ |
| Known as | CBD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07023744 ↗ |